Komet Resources Inc.  {TSX.V: KMT} announced a new set of results from its drilling program completed on the Dabia South permit (previously known as Moussala) in Mali. 

Notable drill intercepts include: 2.02 g/t Au over 62 m; 1.16 g/t Au over 67 m; and 3.43 g/t Au over 12 m.

Komet intersects 2.02 g/t gold over 62 m and 1.26 g/t over 67 m on Dabia South in Mali

.

.

Quebec, May 2, 2017 – Komet Resources Inc.  {TSX.V: KMT} is pleased to announce a new set of results from its drilling program completed on the Dabia South permit (previously known as Moussala) in Mali. 

‘

The new results from RC drilling (intercept true widths not determined) are from the central and eastern portion of the gold-rich Kabaya structure that runs north-south across the permit.

.

The structure has now been traced over a strike length of 500 m and a width of 230 m. Notable drill intercepts include: 2.02 g/t Au over 62 m; 1.16 g/t Au over 67 m; and 3.43 g/t Au over 12 m. Other significant results are presented in the table on the website,  http://kometgold.com

Regarding these new results Mr. André Gagné, president and CEO, commented: Samples were analysed by fire assay with AA finish on 50 g sample aliquots at the SGS Laboratory in Bamako, Mali. Drilling supervision and sampling at the drill site were performed by qualified technical staff. The QA/QC program and the processing of results were designed by qualified geologists according to NI 43-101 regulation standards and best industry practices. One blank or standard or duplicate sample was inserted for every 20 samples analysed.

.

More information about the corporation is available at: http://kometgold.com.

.

.

.

.

.

Scorpio Gold Corp. {TSX.V: SGN} announced its operating results for the first quarter of 2017 at its 70% owned Mineral Ridge project, located in Nevada.

Gold and silver production in Q1 2017 totalled 5,741 ounces and 2,854 ounces, respectively. The lower metal production in Q1 2017 is attributed to fewer tons being mined and processed from the existing pits, due to higher strip ratios that constrain how quickly benches can be mined.

Scorpio Gold Produces 5,741 Ounces of Gold in First Quarter 2017 at the Mineral Ridge Operation, Nevada

Vancouver, April 28 2017 – Scorpio Gold Corp. {TSX.V: SGN} announces its operating results for the first quarter (“Q1”) of 2017 at its 70% owned Mineral Ridge project, located in Nevada.

Gold and silver production in Q1 2017 totalled 5,741 ounces and 2,854 ounces, respectively. The lower metal production in Q1 2017 is attributed to fewer tons being mined and processed from the existing pits, due to higher strip ratios that constrain how quickly benches can be mined.

Brian Lock, interim CEO, reports, “The first quarter production at Mineral Ridge was affected by a slowdown in mining and processing while the project awaits approval of the amendment to its revised Plan of Operations, which is pending from applicable regulatory authorities. The Custer pit and other areas for which permitting is outstanding, will be evaluated for economics of associated mining timelines when permits are received.”

Production in 2017 is scheduled from the Mary LC pit and from the Bluelite and Brodie satellite pits.

Key Operating Statistics
Q1 2017 Q1 2016 %Change
Mining operations

Mary LC pit
Ore tonnes mined 130,446 146,872 -11.2%
Waste tonnes mined 927,786 703,030 32.0%
Total mined 1,058,232 649,902 24.5%
Strip Ratio 7.1 4.8 47.9%

Satellite pits
Ore tonnes mined 7,255 103,252 93.0%
Waste tonnes mined 67,208 227,056 70.4%
Total mined 74,463 330,308 -77.5%
Strip Ratio 9.3 2.2 322.7%

Total producing pits
Ore tonnes mined 137,701 250,124 -44.9%
Waste tonnes mined 994,994 930,086 -4.0%
Total mined 1,132,695 1,180,210 -4.0%
Strip Ratio 7.2 3.7 94.6%

Pits under development
Ore tonnes mined 178 – 100.0%
Waste tonnes mined (pre-stripping) 212,595 55,622 282.2%
Total mined 212,773 55,622 282.5%

Total mining operations
Ore tonnes mined 137,879 250,124 -44.9%
Waste tonnes mined 1,207,589 985,708 22.5%
Total mined 1,345,468 1,235,832 8.9%

Processing
Tonnes processed 138,392 251,587 -45.0%
Gold head grade (g/t) 1.70 1.65 3.0%
Ounces produced
Gold 5,741 8,508 -32.5%
Silver 2,854 3,921 –27.2%
Recoverable(1) gold (ounces) placed on pad 5,175 9,032 -42.7%

(1) A weighted average metallurgical recovery factor has been applied to the estimated contained ounces crushed and placed on the leach pad based on the pit from which the ore was mined.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%). Mineral Ridge is currently in production as a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted on short notice.

Scorpio Gold’s Chairman, Peter J. Hawley, PGeo., is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Brian Lock,
Interim CEO

For further information contact:
Chris Zerga, President
+1 819 825 7618

Website: www.scorpiogold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The Company relies on litigation protection for forward-looking statements. This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “suggest”, “indicate” and other similar words or statements that certain events or conditions “may” or “will” occur, and include, without restriction, any statements regarding the Company receiving approval of its pending Plan of Operations amendment. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks involved in mineral exploration and development programs, risks involved in mineral processing; risks related to open pit mining and heap leach processing operations, obtaining the required permits to expand and extend mining activities and those risk factors outlined in the Company’s Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.
Copyright © 2012 SCORPIO GOLD CORPORATION (TSX: SGN) All rights reserved.

For more information please visit our website at http://www.scorpiogold.com/

or send email to scorpio@scorpiogold.com

Bitcoin {BTC} has put recent setbacks behind it and smashed through the US $ 1,400 barrier to currently rest at US $1,407.

This is despite recent moves by the Chinese government to prevent trading and speculation in Bitcoin.

Bitcoin {BTC} has put recent setbacks behind it and smashed through the US $ 1,400 barrier to currently rest at US $1,407.

This is despite recent moves by the Chinese government to prevent trading and speculation in Bitcoin.

Other crypto currencies are also rising quickly, in particular Dash, and one wonders whether this is another mania, or genuine investment?

Time will tell.

Avalon Advanced Materials Inc {TSE: AVL} Director Don Bubar purchased 100,000 shares of the stock in a transaction on Friday, April 28th. The stock was acquired at an average price of C$0.15 per share, with a total value of C$15,000.00.

Avalon Advanced Materials Inc {TSE: AVL} Director Don Bubar purchased 100,000 shares of the stock in a transaction on Friday, April 28th. The stock was acquired at an average price of C$0.15 per share, with a total value of C$15,000.00.

Don Bubar has also recently made the following purchases:

On Monday, April 24th, purchased 50,000 shares of Avalon Advanced Materials stock. The stock was acquired at an average price of C$0.16 per share, with a total value of C$8,000.00.
On Tuesday, April 25th, 50,000 shares of Avalon Advanced Materials stock. The stock was acquired at an average price of C$0.15 per share, with a total value of C$7,500.00.
On Tuesday, April 4th, 50,000 shares of Avalon Advanced Materials stock. The stock was acquired at an average price of C$0.16 per share, with a total value of C$8,000.00.
On Thursday, March 23rd, purchased 50,000 shares of Avalon Advanced Materials stock. The stock was acquired at an average price of C$0.16 per share, with a total value of C$8,000.00.

Condor Gold Plc {AIM: CNR} a gold exploration and development company whose flagship La India Project in Nicaragua hosts a  mineral resource of 2.31 M oz gold, announced it has qualified for and expects trading to commence on the OTCQX^® Best Market in the U.S.

Zenyatta Ventures  {TSX.V: ZEN}   announced that the completed flotation pilot testing portion of the ongoing metallurgical work has yielded successful results.

The metallurgical testing is part of the pre-feasibility work for the Albany Graphite Deposit located in Northeastern Ontario, Canada.

Zenyatta Successfully Completes Flotation Pilot Testing Portion of Metallurgical Work on Albany Graphite Deposit.

.

.

Neometals Ltd [ASX: NMT] announced that neither of its joint ventures in RIM have accepted that offer to purchase their 13.6% holding in the Mt. Marion lithium project within the offer period in the terms of the pre-emptive rights procedures under the Shareholders Agreement in respect of RIM.

Neometals is now entitled within the next 60 to dispose of its equity interest in RIM to a third party on terms no less favourable to Neometals than those offered to its joint venture partners.

Neometals Ltd [ASX: NMT] announced on 7th April 2017 that it had issued an offer by way of notice of sale to its joint venture partners of all its remaining 13.8% interest in Reed Industrial Minerals Pty Ltd, the holder of the Mt Marion Lithium Project, for a sale price of US$96,001,080.

.

Neometals now announces that neither of its joint ventures in RIM have accepted that offer within the offer period in the terms of the pre-emptive rights procedures under the Shareholders Agreement in respect of RIM.

.

As neither joint venturer has exercised their rights, Neometals is now entitled within the next sixty days to dispose of its equity interest in RIM to a third party on terms no less favourable to Neometals than those offered to its joint venture partners.

.

Neometals is now in discussions with interested third parties and will advise the market of any material developments.

.

.

.

.

.

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced that it has commenced a phase 2 trial to evaluate the efficacy of VGX-3100 in patients with pre-cancerous lesions of the vulva, or vulvar intraepithelial neoplasia (VIN).

VGX-3100 is an immunotherapy that targets human papillomavirus (HPV)

New study expands VGX-3100 program for evaluating therapeutic applications in HPV-related pre-cancers with high medical need

VGX-3100 previously demonstrated efficacy

in regressing HPV-related cervical pre-cancer

PLYMOUTH MEETING, Pa. – April 24, 2017 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced that it has commenced a phase 2 trial to evaluate the efficacy of VGX-3100 in patients with pre-cancerous lesions of the vulva, or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied for the treatment of HPV-related pre-cancerous lesions and persistent HPV infection that causes these lesions. 

VIN has a very low rate of spontaneous, or natural, regression − below 5%. Currently there are no FDA approved non-surgical treatments for pre-cancerous lesions of the vulva. Surgery, the most common treatment, is associated with high rates of disease recurrence and can cause disfigurement, long-term pain, and psychological distress for the women who undergo the procedure. VIN recurs in approximately one of every two patients who undergo surgical treatment.

This randomised, open label phase 2 study will assess the efficacy of VGX-3100 in 36 women with high-grade HPV-related vulvar lesions. The immunotherapy will be administered with Inovio’s CELLECTRA® intramuscular delivery device. The primary endpoint of the study is histologic clearance of high-grade lesions and virologic clearance of the HPV virus in vulvar tissue samples. The study will also evaluate safety and tolerability of VGX-3100.

Inovio’s immunotherapy aims to address the unmet medical need for VIN by providing a non-surgical option for women with this disease. In a previously conducted phase 2b randomized, placebo controlled study of 167 women with HPV-associated cervical pre-cancer, VGX-3100 led to a significantly higher rate of lesion regression and clearance of the underlying HPV viral infection. Inovio plans to initiate a phase 3 study of VGX-3100 as a treatment for high grade cervical dysplasia in 2017, and the treatment of VIN represent an important additional indication for its lead product.

Dr. Robert Edwards, Chair of Obstetrics and Gynecology at the University of Pittsburgh School of Medicine at Magee-Women’s Hospital and Professor of Medicine in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh, School of Medicine, said, “HPV-induced VIN is one of the major causes of morbidity for young and middle-aged women with HPV-induced pre-cancer. It is associated with repetitive need for surgery, multiple biopsies, and a major cause of pain and sexual dysfunction.” 

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “Inovio’s VGX-3100 may provide the first approved non-surgical treatment option for women with this HPV-related pre-cancer with a high recurrence rate. My optimism is based on our phase 2b efficacy results finding clearance of lesions and the HPV virus in many subjects in our evaluation of VGX-3100 in women with high grade cervical dysplasia. Our ultimate goal is for VGX-3100 to become the “go-to” immunotherapy to treat all major HPV-related premalignant diseases.” 

About Vulvar Pre-Cancers

If left untreated vulvar pre-cancers can progress to invasive cancer of the vulva. Approximately 27,000 cases of HPV-related vulvar pre-cancers occur in the U.S. each year and about 12,000 to 24,000 cases in Europe each year. HPV-16 and/or HPV-18 are involved in about 80% of HPV-related vulvar pre-cancers cases in the U.S. and Europe. Once vulvar pre-cancers develop, spontaneous regression (i.e. natural disappearance of the lesion) is rare and occurs in 1.5% to 5% of cases. An estimated 6,000 new cases of vulvar cancer occur in the U.S. each year with about 50% to 80% of those being HPV-associated. About 1,110 deaths occur annually due to vulvar cancer in the U.S. Standard of care treatment of vulvar pre-cancer usually involves surgery, which has significant physical and psychosocial impacts in women (e.g. severe pain, disfigurement, sexual dysfunction), and the success of such surgery is marginal, as the recurrence rate of high grade vulvar pre-cancer is extremely high, i.e. about 50% three years post-treatment.

About VGX-3100

VGX-3100 is an HPV-specific immunotherapy that is being developed as a non-surgical treatment for high-grade HPV-caused pre-cancers and other related underlying persistent HPV infections. VGX-3100 works in vivo to activate functional, antigen-specific, CD8 killer T-cells to clear persistent HPV infection and cause regression of pre-cancerous lesions. In a phase 2 trial to treat cervical dysplasia, VGX-3100 demonstrated clinical efficacy and was generally well tolerated, without the side effects and obstetric risks associated with surgical excision. VGX-3100 is a first-in-class HPV-specific immunotherapy that targets the underlying cause of HPV-related pre-cancers, providing an opportunity for women to reduce their risk of cervical cancer without undergoing an invasive surgical procedure.

About Inovio Pharmaceuticals, Inc. 

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. The company is advancing an expanding product pipeline in both early and late stage clinical studies. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

CONTACT:

Bernie Hertel

+1 858 410 3101

bhertel@inovio.com

# # # #

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, including the immunotherapy VGX-3100, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Scorpio Gold Corp. {TSX.V: SGN}  announced its financial results for the fourth quarter (“Q4”) and year ended December 31, 2016.

They are also filed on www.sedar.com and on the company website.

Scorpio Gold Reports Fourth Quarter and Provides Year-End Financial Results for 2016

Vancouver, April 24, 2017 – Scorpio Gold Corp. {TSX.V: SGN} is pleased to announce its financial results for the fourth quarter (“Q4”) and year ended December 31, 2016. This press release should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2016 and Management’s Discussion & Analysis (“MD&A”) for the same period, available on the Company’s website at www.scorpiogold.com and under the Company’s name on SEDAR at www.sedar.com. All monetary amounts are expressed in US dollars unless otherwise specified.

PERFORMANCE HIGHLIGHTS:
Q4 2016 Q4 2015 2016 2015
$ $ $ $
Revenue (000’s) 7,569 10,828 42,759 44,587
Mine operating earnings (000’s) 1,529 1,452 9,638 7,691
Net (loss) earnings (000’s) (4,270) (4,665) 339 (17,986)
Basic and diluted loss per share (0.03) (0.03) (0.00) (0.13)
Adjusted net earnings(1) (000’s) 804 712 6,481 4,591
Adjusted basic and diluted net earnings per share(1) 0.00 0.00 0.03 0.02
Adjusted EBIDTA(1) (000’s) 1,617 2,665 9,510 10,611
Adjusted basic and diluted EBIDTA per share(1) 0.01 0.01 0.05 0.06(2)
Cash flow from (used in) operating activities(000’s) 582 (31) 11,000 11,192
Total cash cost per ounce of gold sold(1) 873 786 881 781
Gold ounces produced 8,301 9,503 36,879 39,690
2016 HIGHLIGHTS
36,879 ounces of gold produced at the Mineral Ridge mine compared to 39,690 ounces during 2015.
Revenue of $42.8 million compared to $44.6 million during 2015.
Total cash cost per ounce of gold sold(1) of $881 compared to $781 during 2015.
Mine operating earnings of $9.6 million compared to $7.7 million during 2015.
Net earnings of $0.3 million ($0.01 basic and diluted net loss per share) after non-cash impairment charges of $3.6 million, $1.4 million net loss on write-off and disposal of mining assets and $1.0 million loss on litigation, compared to a net loss of $18.0 million ($0.13 basic and diluted per share) after non-cash impairment charges of $21.9 million during 2015.
Adjusted net earnings(1) of $6.5 million ($0.03 basic and diluted per share) compared to $4.6 million ($0.02 basic and diluted per share) during 2015.
Adjusted EBITDA(1) of $9.5 million ($0.05 basic and diluted per share) compared to $10.6 million ($0.06(2) basic and diluted per share) during 2015.
Cash flow from operating activities of $11.0 million compared to $11.2 million during 2015.

FOURTH QUARTER 2016 (“Q4”) HIGHLIGHTS
8,301 ounces of gold produced at the Mineral Ridge mine compared to 9,503 ounces in Q4 of 2015.
Revenue of $7.6 million in Q4 of 2016 compared to $10.8 million during Q4 of 2015.
Total cash cost per ounce of gold sold(1) of $873 in Q4 of 2016 compared to $786 during Q4 of 2015.
Mine operating earnings of $1.5 million in both Q4 of 2016 and 2015.
Net loss of $4.3 million ($0.03 basic and diluted per share), compared to $4.7 million ($0.03 basic and diluted per share) during Q4 of 2015. During Q4 of 2016, impairments of $3.6 million on the mining assets, $1.0 million loss on litigation and $0.4 million write-off of mining assets were recorded. During Q4 of 2015, impairments of $4.9 million were recorded on the mining assets.
Adjusted net earnings(1) of $0.8 million ($0.00 basic and diluted per share) compared to $0.7 million ($0.00 basic and diluted per share) during Q4 of 2015.
Adjusted EBITDA(1) of $1.6 million ($0.01 basic and diluted per share) compared to $2.7 million ($0.01 basic and diluted per share) during Q4 of 2015.
Cash flow from operating activities of $0.6 million compared to close to nil in Q4 of 2015.
(1) This is a non-IFRS measure; refer to Non-IFRS Measures section of this press release and the Company’s Management Discussion & Analysis for a complete definition and reconciliation to the Company’s financial statements.
(2) This number was adjusted following a change in the calculation of the non-controlling interest’s share of MRG’s net income (loss). See the section of the MD&A entitled “Equity” for a description of the resulting changes.

2017 Outlook

Based on the Company’s current mine plan, it currently anticipates mining of gold at Mineral Ridge through to August 2017. Due to permitting timelines, the Company anticipates production of gold at Mineral Ridge to be 20 — 25,000 ounces from the Mary LC, Brodie and Bluelite south pits. The Custer pit and other areas for which permitting is outstanding, are not included in this production estimate and will be evaluated for economics of associated mining timelines when permits are received. Given the Company’s short remaining life of mine, it is taking initiatives to extend the life of mine at Mineral Ridge through additional drilling to expand its resources, applying for permits to expand and extend current operations of new and existing pits, expanding the heap leach pad, and conducting a drilling program on its leach pad to determine if the leach pad material is amenable for further gold recovery using milling processes.

NON-IFRS MEASURES

The discussion of financial results in this press release includes reference to Adjusted net earnings, Adjusted EBITDA, Total cash cost per ounce of gold sold which are non-IFRS measures. The Company provides these measures as additional information regarding the Company’s financial results and performance. Please refer to the Company’s MD&A for the year ended December 31, 2016 for definitions of these terms and a reconciliation of these measures to reported International Financial Reporting Standards (“IFRS”) results.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%). Mineral Ridge is currently in production as a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted on short notice.

Scorpio Gold’s Chairman, Peter J. Hawley, PGeo., is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Brian Lock,
Interim CEO

For further information contact:
Chris Zerga, President
+1 819 825 7618
czerga@scorpiogold.com
Website: www.scorpiogold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The Company relies on litigation protection for “forward-looking” statements. This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “suggest”, “indicate” and other similar words or statements that certain events or conditions “may” or “will” occur, and include, without limitation, statements regarding the Company’s plans with respect to the exploration, development and exploitation of its Mineral Ridge mine, including any forecasts regarding future production or costs related thereto. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks relating to operation of a gold mine, including unanticipated changes in the mineral content of materials being mined; unanticipated changes in recovery rates; changes in project parameters; failure of equipment or processes to operate as anticipated; the failure of contracted parties to perform; availability of skilled labour and the impact of labour disputes; obtaining the required permits to expand and extend mining activities; delays in obtaining governmental approvals; changes in metals prices; the availability of cash flows or financing to meet the Company’s ongoing financial obligations; unanticipated changes in key management personnel; changes in general economic conditions; other risks of the mining industry and those risk factors outlined in the Company’s Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.

 
Copyright © 2012 SCORPIO GOLD CORPORATION (TSX: SGN) All rights reserved.

For more information visit  http://www.scorpiogold.com

or send email to scorpio@scorpiogold.com

Dash (short for Digital cash) has grown a phenomenal 2500% so far in 2017!

The cryptocurrency is now valued at over $100 per coin. 

To read the full article please CLICK HERE

Eguana Technologies Inc. {TSX.V: EGT}, one of the technology leaders in power conversion and control systems for distributed energy storage, is pleased to announce the addition of Mr. Steven Vaccaro to its business development team.
Mr. Vaccaro brings over 20 years’ experience in the solar and renewable energy sectors.

Eguana Technologies Brings in New Business Development Manager Amid Growing Demand

 
CALGARY, ALBERTA- April 20, 2017) – Eguana Technologies Inc. {TSX.V: EGT}, one of the technology leaders in power conversion and control systems for distributed energy storage, is pleased to announce the addition of Mr. Steven Vaccaro to its business development team.

 
Mr. Vaccaro brings over 20 years’ experience in the solar and renewable energy sectors having held senior executive and board level positions. “A true veteran of the solar and energy industry, Steven brings a proven track record of initiating and executing deals in both the North American and international marketplace” commented Justin Holland, CEO of Eguana. “With an established personal network spanning global solar and commercial real estate, we are encouraged and excited with the opportunities Steven has already presented.”

 
“Having driven successful businesses in energy efficiency and solar energy, storage is the next big market. I’ve followed Eguana for some time and believe they have excellent products for the residential and commercial storage markets” added Vaccaro.
As part of Mr. Vaccaro’s compensation, he will be issued 250,000 options pursuant to the company’s stock option Plan.

 
About Eguana Technologies Inc.
Eguana Technologies Inc. {TSX.V:EGT} designs and manufactures high performance power controls for residential and commercial energy storage systems. Eguana has more than 15 years’ experience delivering grid edge power electronics for fuel cell, photovoltaic and battery applications and delivers proven, durable, high quality solutions from its high capacity manufacturing facilities in Europe and North America.

 
With thousands of its proprietary energy storage inverters deployed in the European and North American markets, Eguana is one of the leading suppliers of power controls for solar self-consumption, grid services and demand charge applications at the grid edge.

To learn more, please visit www.EguanaTech.com

 
Forward Looking Information
Forward-looking information is not a guarantee of future performance and involves a number of risks and uncertainties. Many factors could cause the Company’s actual results, performance or achievements, or future events or developments, to differ materially from those expressed or implied by the forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date hereof. Readers are also directed to the Risk Factors section of the Company’s current Annual Information Form which may be found on its website or at sedar.com The Company does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 
CONTACT
Justin Holland
CEO, Eguana Technologies Inc.
+1 416 728 7635

Kootenay Silver Inc. {TSX.V: KTN}  announced that amended permits are in place and preparations for the previously announced 7,500-meter drill program are underway at its 100% owned La Cigarra silver project, located in Chihuahua State, Mexico.

KOOTENAY ANNOUNCES DRILL PROGRAM TO TARGET RESOURCE EXPANSION AT LA CIGARRA SILVER PROJECT, MEXICO

 
Kootenay Silver Inc. {TSX.V: KTN} is pleased to announce that amended permits are in place and preparations for the previously announced 7,500-meter drill program (the “Program”) are underway at its 100% owned La Cigarra silver project, located in Chihuahua State, Mexico.

Drilling will commence in approximately two weeks and operate concurrently with ongoing geological mapping and sampling programs on peripheral target areas, which will be drill tested later in the year. The program is designed to expand on the reported Measured and Indicated silver resource, which currently stands at 18.5 million tonnes grading 86.3 gpt containing 51.5 million ounces and an Inferred silver resource of 4.45 million tonnes grading 80.0 gpt containing 11.4 million ounces (see Northair News Release dated January 14, 2015 or SEDAR for information on the NI 43-101 technical report).
The Program will focus on the expansion of the La Cigarra mineral resource by first targeting an 800-meter gap between the Las Venadas Zone and the south end of the resource (Las Carolinas Zone). This includes the southern boundary of Las Carolinas where hole 155 returned 23.45 meters of 138.3 gpt silver. (See Northair News Release dated Dec 15, 2014). Drilling will begin the Las Venadas Zone, where significant soil and rock geochemical anomalies and historic mine workings occur and work northward on trend towards the Las Carolinas Zone.
Sampling and QA/QC

All technical information for the La Cigarra exploration program is obtained and reported under a formal quality assurance and quality control (“QA/QC”) program. Samples are taken under the direction of qualified geologists and stored in sealed bags. Samples are delivered by the Company via courier to ALS Minerals (“ALS”) in Chihuahua. The samples are dried, crushed and pulverised with the pulps being sent airfreight for analysis by ALS in Vancouver B.C. Systematic assaying of standards is performed for precision and accuracy. Analysis for silver, zinc, lead and copper and related trace elements was done by ICP four acid digestion, with gold analysis by 30-gram fire assay with an AA finish.

Qualified Persons

The Kootenay technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 (Standards of Disclosure for Mineral Projects) and reviewed on behalf Kootenay by James McDonald, P.Geo, President, CEO & Director for Kootenay, a Qualified Person.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Kootenay Silver Inc.
Kootenay Silver Inc. is an exploration company actively engaged in the discovery and development of mineral projects in the Sierra Madre Region of Mexico and in British Columbia, Canada. Supported by one of the largest portfolios of silver assets in Mexico, Kootenay continues to provide its shareholders with significant leverage to silver prices. The Company remains focused on the expansion of its current silver resources, new discoveries and the near-term economic development of two of its priority silver projects located in prolific mining districts in Sonora, State and Chihuahua, State, Mexico, respectively.
For additional information, please contact:
James McDonald, CEO and President at +1 403 880 6016
Ken Berry, Chairman at +1 604 601 5652
or visit: www.kootenaysilver.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

The information in this news release has been prepared as at April 18, 2017. Certain statements in this news release, referred to herein as “forward-looking statements”, constitute “forward-looking statements” under the provisions of Canadian provincial securities laws. These statements can be identified by the use of words such as “expected”, “may”, “will” or similar terms.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by Kootenay as of the date of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Many factors, known and unknown, could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as otherwise required by law, Kootenay expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Kootenay’s expectations or any change in events, conditions or circumstances on which any such statement is based.
Cautionary Note to US Investors: This news release may contain information about adjacent properties on which we have no right to explore or mine. We advise U.S. investors that the SEC’s mining guidelines strictly prohibit information of this type in documents filed with the SEC. U.S. investors are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on our properties. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

This press release uses the terms “Measured”, “Indicated”, and “Inferred” resources. United States investors are advised that while such terms are recognized and required by Canadian regulations, the United States Securities and Exchange Commission does not recognize them. “Inferred Mineral Resources” have a great amount of uncertainty as to their existence, and as to their economic and legal feasibility. It cannot be assumed that all or any part of an Inferred Mineral Resource will ever be upgraded to a higher category. Under Canadian rules, estimates of Inferred Mineral Resources may not form the basis of feasibility or other economic studies. United States investors are cautioned not to assume that all or any part of Measured or Indicated Mineral Resources will ever be converted into Mineral Reserves. United States investors are also cautioned not to assume that all or any part of a Mineral Resource is economically or legally mineable.

Cartier Resources {TSX.V: ECR} are the subject of a research note update from the Canadian Mine analysis.com website.

The note updates their findings since the Agnico Eagle investment, made recently, and the recent fundraising, and takes into account the current gold price.

To read the full article please CLICK HERE

or paste the folowing code into a browser

http://www.ressourcescartier.com/en/MediaHandler.ashx?MediaId=1b403b75-4b15-44dd-abb9-10a78f460bd9

The price of metallurgical (coking) coal used in steelmaking has surged to a record high on the back of demand following the bad weather disruption to Australian production.

The price is now $420 in Canadian dollar terms,a new record high, and makes Canadian based coal stocks like our Colonial Coal {TSX: CAD} look cheap in asset valuation terms.

The price of metallurgical (coking) coal used in steelmaking has surged to a record high on the back of demand following the bad weather disruption to Australian production.

The price is now $420 in Canadian dollar terms,a new record high, and makes Canadian based coal stocks like our Colonial Coal {TSX: CAD} look cheap in asset valuation terms. The same can be said for Australian coal miners as the same difference to the US dollar also applies.

Colonial estimate the cost of producing and transporting a ton of their premium coking coal FOB at the port to be around CAD $140 – 150, which results in a huge margin at the current price.

Clearly once Australian production recovers to previous levels there will be a fall in price, but in the meantime one can only hope that with the spotlight currently on previously unloved coal, the valuations of companies in the sector will become more realistic given the current low price attributed to each ton of resource in the ground.

Colonial recently financed CAD $7.5 million, and are looking to conduct a drill campaign this summer, so this looks an excellent time for them to add additional tons to their current resources.

Neometals {ASX: NMT} Continued their on-market share buyback program by purchasing another 120,684 shares.

The total ASX approved buyback is 28 million shares.

Neometals {ASX: NMT} Continued their on market share buyback program by purchasing another 120,684 shares.

The total ASX approved buyback is 28 million shares.

Interestingly, the company, who are selling their 13.8% stake in Mt. Marion for AU $125 million, plus their cash on hand of AU $61 million, is almost exactly worth their current market cap, so no arbitrage opportunity currently, but we will keep a close eye on the SP just in case.

Uranium Energy Corporation {NYSE: UEC} announced that the Environmental Protection Agency has approved the 5,384-acre aquifer exemption request for the Company’s Burke Hollow Project in South Texas.

Burke Hollow is the third project to be developed as part of the Company’s hub-and-spoke strategy that is designed for low-cost in-situ recovery.

Uranium Energy Corp Receives Aquifer Exemption Approval for its Burke Hollow ISR Project in South Texas

Corpus Christi, TX, April 5, 2017 – Uranium Energy Corporation {NYSE: UEC} is pleased to announce that the Environmental Protection Agency has approved the 5,384-acre aquifer exemption request for the Company’s Burke Hollow Project in South Texas.

Burke Hollow is the third project to be developed as part of the Company’s hub-and-spoke strategy that is designed for low-cost in-situ recovery (“ISR”) production to be processed at the nearby Hobson plant.

The approval comes shortly after the project’s 11,000-acre Mine Area Permit was approved in December 2016 by the Texas Commission on Environmental Quality (“TCEQ”). Two additional disposal well permits were also issued in July 2015 to make up three of the four major permits required for the project. The last major approval is the Radioactive Material License which remains under technical review with the TCEQ.

The Company’s 2017 drilling campaign at Burke Hollow commenced on April 3, earlier this week, with two contracted drill rigs and plans to drill up to 100 delineation and exploration holes. The primary objective of this campaign is to complete the exploration and delineation drilling phase of two closely-related Goliad Lower B trends which will constitute Burke Hollow Production Area 1. The two Lower B trends have been proven to extend over a distance of 1.7 miles. The northwestern side of the orebody remains open-ended and only lightly explored, with good potential for extension for up to an additional 3,000 feet.

About Uranium Energy Corporation

Uranium Energy Corp is a U.S.-based uranium mining and exploration company. The Company’s fully-licensed Hobson processing facility is central to all of its projects in South Texas, including the Palangana ISR mine, the permitted Goliad ISR project and the development-stage Burke Hollow ISR project.

Additionally, the Company controls a pipeline of advanced-stage projects in Arizona, Colorado and Paraguay. The Company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining.

Contact:

Investor Relations
+1 866 748 1030
info@uraniumenergy.com

Stock Exchange Information:
NYSE MKT: UEC
Frankfurt Stock Exchange Symbol: U6Z
WKN: AØJDRR
ISN: US916896103

Safe Harbour Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of exploration activities, variations in the underlying assumptions associated with the estimation or realization of mineral resources, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labor disputes and other risks of the mining industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes or claims limitations on insurance coverage. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. For forward-looking statements in this news release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities.

Bitcoin {BTC} has shrugged of its recent setbacks, and the price has risen back over $1,201, showing the buying strength that appears every time there is a dip.

Bitcoin has soon overcome the difficulties imposed by the the Chinese government restricting trading  by imposing a transaction tax, and the US SEC declining a Bitcoin ETF proposal.

Bitcoin {BTC} has shrugged of its recent setbacks, and the price has risen over $1,201, showing the buying strength that appears every time there is a dip.

Bitcoin has shrugged off the recent setbacks of the Chinese government restricting margin trading  by imposing a transaction tax, and the US SEC declining a Bitcoin ETF proposal.

After a short run of being more valuable than gold, Bitcoin fell back quickly, but is now advancing once again toward the gold price, a situation I find quite incredible.

I do not see Bitcoin as a tangible asset in the same way as gold, although you could argue it’s an easier way to move money around the world, and is being traded for that reason, rather than investment value.

Inovio Pharmaceuticals, Inc. {NASDAQ: INO}  announced  preliminary results from the expanded stage of its phase I study, EBOV-001.

The results across both stages of the trial, including both intramuscular and intradermal delivery, demonstrated that 95% (170/179) of evaluable subjects generated an Ebola-specific antibody immune response, with the mean antibody titer comparable or superior to those reported from viral vector-based Ebola vaccines.

Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
PLYMOUTH MEETING, Pa. – April 11, 2017 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO}  announced today preliminary results from the expanded stage of its phase I study, EBOV-001.

The expanded study examined different regimens of its Ebola DNA vaccine INO-4201 using intradermal (skin) administration. The results across both stages of the trial, including both intramuscular and intradermal delivery, demonstrated that 95% (170/179) of evaluable subjects generated an Ebola-specific antibody immune response, with the mean antibody titer comparable or superior to those reported from viral vector-based Ebola vaccines.

Importantly, Inovio’s Ebola vaccine was well-tolerated with a favorable safety profile compared to viral vector-based Ebola vaccines, some of which have been associated with serious adverse events including myalgia, arthralgia, fever, and rash. Furthermore, their faster construct design, ability to continue to boost immune responses and protection with additional administrations, easier scalability of manufacturing, and better product thermal stability make DNA vaccines an attractive platform to rapidly respond to emerging global infectious diseases.

Previously, Inovio reported positive safety and immune response data in the first set of 75 healthy volunteers administered with INO-4212 (60 delivered intramuscularly and 15 intradermally). Based on that result Inovio enrolled an additional 125 subjects in a second stage of this trial to further characterize and optimize immunization regimens using intradermal delivery, which is well-suited for this preventive Ebola DNA vaccine. Across the two stages, 88% (50/57) of evaluable intramuscular subjects generated an Ebola-specific antibody immune response; 97% (119/122) of evaluable intradermal subjects generated an Ebola-specific antibody immune response.

In an accompanying preclinical study, INO-4201 protected 100% of rhesus monkeys challenged with a lethal dose of the Ebola virus following vaccination with two intradermal doses of INO-4201.

Dr. Scott White, Inovio’s Vice President of Clinical Development, is presenting this data today at the World Vaccine Congress in Washington, D.C.

Dr. J. Joseph Kim, Inovio’s President & CEO, said, “This response rate mirrors the high response rates we recently reported from our MERS and Zika clinical studies, reinforcing Inovio’s ability to rapidly design and construct vaccines against emerging global infectious diseases. With these strong results from 200 subjects and positive preliminary preclinical data from several animal species, we plan to meet with regulators this year regarding a path forward for the licensure of our Ebola product.”

Inovio’s Ebola vaccine program is funded by a $45 million contract received from DARPA to develop an Ebola vaccine and DNA-based monoclonal antibody therapy. A more detailed data set and analysis from this study is being prepared for publishing in a peer-reviewed journal.

About Ebola

The Ebola virus causes periodic outbreaks of a highly contagious and lethal human infectious disease marked by severe hemorrhagic fever, with a mortality rate that ranges between 50% and 90%. The infection typically affects multiple organs in the body and is often accompanied by severe bleeding. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. At present there are no FDA-approved pre- or post-exposure interventions available in the event of an outbreak, laboratory accident, or deliberate misuse. The Ebola virus is classified as a Category A Priority Pathogen by the Centers for Disease Control and Prevention. This designation prescribes an accelerated development pathway for FDA approval that determines efficacy based on two different validated animal studies followed by clinical evaluation in phase I and phase II trials to establish safety and immunogenicity for use in humans.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, visit www.inovio.com

CONTACT:

Bernie Hertel
+1 858 410 3101
bhertel@inovio.com
# # # #
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, including the Ebola immunotherapy INO-4212, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Avalon Advanced Materials Inc. {TSX: AVL} announced that it has commenced a 10 hole, 2,000 metre diamond drilling program on its 100% owned Separation Rapids Lithium Project  near Kenora, Ontario.

The program is expected to be completed over the next 6-8 weeks, following which an updated resource estimate will be prepared. 

AVALON COMMENCES 2,000 METRE DRILLING PROGRAM ON SEPARATION RAPIDS LITHIUM PROJECT, KENORA, ONTARIO

 
Toronto, Ontario – Avalon Advanced Materials Inc. {TSX: AVL} is pleased to announce that it has commenced a 10 hole, 2,000 metre diamond drilling program on its 100% owned Separation Rapids Lithium Project (the “Project”) near Kenora, Ontario.

The program is expected to be completed over the next 6-8 weeks, following which an updated resource estimate will be prepared. The drilling program has a number of specific objectives including:

Expanding the existing mineral resource of lithium (petalite) pegmatite mineralization which is open along strike and to depth;
Quantifying the lithium mineralization in the resource model associated with lepidolite and other lithium micas versus lithium mineralization associated with petalite;
Testing an undrilled target area 1 kilometre west of the known resource where a showing of petalite pegmatite sampled by the Company in 1997 yielded 1.56% Li2O across 8.9 metres;

Collecting geotechnical data for groundwater studies and mine planning in advance of permitting for site development.

 
Previous exploration work by Avalon in the 1990’s focused only on recovering the lithium mineral petalite as an industrial mineral product for glass-ceramics applications and consequently did not fully account for the lepidolite mineralization in the development model. However, as disclosed in the Company’s news release dated February 6, 2017, recent testwork conducted by Lepidico Ltd. of Perth, Australia (“Lepidico”) using its patented L-Max® hydrometallurgical process technology has successfully produced a battery grade lithium carbonate product from lepidolite sourced from the Separation Rapids property.

There are sub-zones in the Separation Rapids deposit where the lithium is dominantly contained in lepidolite, which can be concentrated separately from the petalite. This offers the potential for production of both a lithium carbonate product from a lepidolite concentrate as well as a lithium hydroxide product from a petalite concentrate, the latter as contemplated in the Company’s Preliminary Economic Assessment (“PEA”), finalised in November, 2016.

The current drilling program will aid in differentiating petalite-dominant versus lepidolite-dominant resources in the block model and contribute to a revised development model for the Project. An updated PEA reflecting the new resource, as well as recent progress on process development work, is planned for this summer.

The technical information included in this news release has been reviewed and approved by the Company’s Vice President, Exploration, Dr. William Mercer, a Qualified Person under NI 43-101.

About Avalon Advanced Materials Inc.

Avalon Advanced Materials Inc. is a Canadian mineral development company specializing in niche market metals and minerals with growing demand in new technology. The Company has three advanced stage projects, all 100%-owned, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, niobium, and zirconium. Avalon is currently focusing on its Separation Rapids Lithium Project, Kenora, ON and its East Kemptville Tin-Indium Project, Yarmouth, NS. Social responsibility and environmental stewardship are corporate cornerstones.

For questions and feedback, please e-mail the Company at ir@AvalonAM.com

or
Phone Don Bubar, President & CEO
+1 416 364 4938.
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements that the drilling program is expected to be completed over the next 6-8 weeks following which an updated resource estimate will be prepared, that it will aid in differentiating petalite-dominant versus lepidolite-dominant resources in the block model and contribute to a revised development model for the Project, that there may be the potential for production of both a lithium carbonate product from a lepidolite concentrate as well as a lithium hydroxide product from a petalite concentrate and that an updated PEA reflecting the new resource as well as recent progress on process development is planned for this summer . Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “potential”, “scheduled”, “anticipates”, “continues”, “expects” or “does not expect”, “is expected”, “scheduled”, “targeted”, “planned”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be” or “will not be” taken, reached or result, “will occur” or “be achieved”. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avalon to be materially different from those expressed or implied by such forward-looking statements. Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made. Although Avalon has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to market conditions, Avalon’s ability to secure sufficient financing to advance and complete the Project, uncertainties associated with securing the necessary approvals and permits in a timely manner, assumptions used in the PEA proving to be inaccurate, uncertainties associated with Avalon’s resource and reserve estimates, uncertainties regarding global supply and demand for lithium and feldspar and market and sales prices, uncertainties associated with securing off-take agreements and customer contracts, uncertainties with respect to social, community and environmental impacts, uncertainties with respect to optimization opportunities for the Project as well as those risk factors set out in the Company’s current Annual Information Form, Management’s Discussion and Analysis and other disclosure documents available under the Company’s profile at www.SEDAR.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Such forward-looking statements have been provided for the purpose of assisting investors in understanding the Company’s plans and objectives and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking statements. Avalon does not undertake to update any forward-looking statements that are contained herein, except in accordance with applicable securities laws.

Neometals {ASX: NMT} has commenced its previously announced share buyback program with an initial purchase of 1.263 million shares at 32 c per share.

This follows their offering for sale for $125 million their 13.8% stake in the Mt.Marion lithium project, WA.

Neometals {ASX: NMT} has commenced its previously announced share buyback program with an initial purchase of 1.263 million shares at 32 c per share.

This follows their offering for sale for $125 million their 13.5% stake in the Mt.Marion lithium project, WA.  If their stake is not taken up by their existing partners in the project, Ganfeng Lithium and ASX listed Mineral Resources Ltd, Neometals may offer it to outside parties.

Under this buyback program, Neometals can purchase 28.1 million shares.